ClinicalTrials.gg
Status unknownNCT02383953Updated Oct 26, 2017

SSAT 054: Non Genetic Factors in the Pathogenesis of IBD in Twins

An observational study in Inflammatory Bowel Disease, Crohn's Disease and Ulcerative Colitis, sponsored by St Stephens Aids Trust. Status unknown at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-26.

Sponsored by St Stephens Aids Trust · Observational

The sponsor has not verified this record recently (last verified Oct 2017), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Family-based
Time perspective
Cross-sectional
Enrollment
200
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to investigate the role of non-genetic factors in the pathogenesis of inflammatory bowel disease.An exploratory study to investigate differences between the epigenome, microbiota and functional immunology in twins discordant for inflammatory bowel disease.

Read the detailed description

Background: The inflammatory bowel diseases (IBD), Crohn's Disease (CD) and Ulcerative Colitis (UC), are debilitating conditions with a complex aetiology. The biggest risk factor for developing IBD is having an affected first degree relative. However when an identical twin is diagnosed with IBD, the other twin goes on to develop the condition in only 20-55% of cases.

Recent research suggests the microbiota the ecosystem of bacteria within the gut may trigger disease in susceptible individuals. Another important research area is the epigenome changes to the structure and regulation of our genome which occur throughout our life. It is known that siblings of Crohn's Disease sufferers have a changes to the immune system characteristic of Crohn';s. However it is not known whether these changes are due to genetic similarity or shared environment. Comparison between mono and dizygotic twins elucidates the relative importance of genetic and environmental factors.

Primary Objective: An exploratory study to investigate differences between the epigenome, microbiota and functional immunology in twins discordant for inflammatory bowel disease.

Study Design: Multicentre basic science study involving human participants

Planned sample size: 200 data subjects (100 twin pairs)

Methodology:

A) Identification of twin pairs where one or both have inflammatory bowel disease via:

  1. IBD Nixon Twin and Multiplex Registry.
  2. Advertising for twin pairs via BSG website and newsletters/patient support groups/social media sites/clinic posters.
  3. Identification by study sites B) Obtaining formal written consent C) Collection of blood, stool and urine.

D) The following analysis will be carried out:

  • Epigenetics (blood) DNA extraction and subsequent methylation analysis and bisulphate conversion with 450 Illumina beadchip assay
  • Functional immunology (blood) - flow cytometry of CD3, CD4 and CD8 cells. (London Twin pairs discordant for Crohn's Disease)
  • 16S rRNA gene sequencing (stool) - of bacterial DNA
  • Metabolomic profiling (Urine and stool) - using Nuclear Magnetic Resonance (NMR) and mass spectrometry E) Collection of dietary history information for the previous 72hr period Study Duration: 2 years (single visit).
02

Conditions studied

  • Inflammatory Bowel Disease
  • Crohn's Disease
  • Ulcerative Colitis

Keywords

  • twins
  • IBD
  • UC
  • CD
03

In context

Inflammatory Bowel Diseases

1,487 studies on the registry are indexed under Inflammatory Bowel Diseases; 434 are open to participants now.

This study's planned enrollment of 200 is above the median of 146 across 659 observational studies indexed under Inflammatory Bowel Diseases.

Browse Inflammatory Bowel Diseases studies →

Lead sponsor

St Stephens Aids Trust is the lead sponsor of 46 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

200

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Monozygotic twins discordant for IBD
  • Monozygotic twins concordant for IBD
  • Dizygotic twins discordant for IBD
  • Dizygotic twins concordant for IBD
  • Healthy controls

Exclusion criteria

Exclusion Criteria:

  • \<18 years old
  • Antibiotics within past 3 months of sample collection
  • Unable to give informed consent
05

Study design

Observational model
Family-based
Time perspective
Cross-sectional
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Difference in DNA methylation patterns between twin pairs

    Time frame: 1 day (1 visit only)

  2. Difference in microbiota composition and metabolomic profiles between IBD phenotypes

    Time frame: 1 day (1 visit only)

  3. Comparison of microbiota composition and metabolic profiles with DNA methylation patterns

    Time frame: 1 day (1 visit only)

  4. Difference in T cell phenotypes and antigen presenting cells between twin pairs discordant for IBD

    Time frame: 1 day (1 visit only)

07

Study locations

1 site
  • Chelsea and Westminster Hosptial
    London, SWIO 9NH, United Kingdom
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02383953
Lead sponsor
St Stephens Aids Trust
Responsible party
Sponsor
First posted
Mar 10, 2015
Start date
May 2015
Primary completion
Oct 2017 (estimated)
Completion
Oct 2017 (estimated)
Last update
Oct 26, 2017

Study contacts

Marcus Harbord, MD
principal investigator · Chelsea and Westminster Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion